



Aalborg Universitet

AALBORG UNIVERSITY
DENMARK

Mobile photoplethysmographic technology to detect atrial fibrillation

Guo, Yutao; Wang, Hao; Zhang, Hui; Liu, Tong; Liang, Zhaoguang; Xia, Yunlong; Yan, Li; Xing, Yunli; Shi, Haili; Li, Shuyan; Liu, Yanxia; Liu, Fan; Feng, Mei; Chen, Yundai; Lip, Gregory Y H; MAFA II investigators; Lip, Gregory Yoke Hong

Published in:

Journal of the American College of Cardiology

DOI (link to publication from Publisher):

[10.1016/j.jacc.2019.08.019](https://doi.org/10.1016/j.jacc.2019.08.019)

Creative Commons License

CC BY-NC-ND 4.0

Publication date:

2019

Document Version

Version created as part of publication process; publisher's layout; not normally made publicly available

[Link to publication from Aalborg University](#)

Citation for published version (APA):

Guo, Y., Wang, H., Zhang, H., Liu, T., Liang, Z., Xia, Y., Yan, L., Xing, Y., Shi, H., Li, S., Liu, Y., Liu, F., Feng, M., Chen, Y., Lip, G. Y. H., MAFA II investigators, & Lip, G. Y. H. (2019). Mobile photoplethysmographic technology to detect atrial fibrillation. *Journal of the American College of Cardiology*, 74(19), 2365-2375. <https://doi.org/10.1016/j.jacc.2019.08.019>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Mobile Health Technology for Atrial Fibrillation Screening Using Photoplethysmography-Based Smart Devices: The HUAWEI Heart study

Yutao Guo, M.D., Ph.D., Hao Wang, M.D., Ph.D., Hui Zhang, M.D., Tong Liu, M.D.,
Ph.D., Zhaoguang Liang, M.D., Ph.D., Yunlong Xia, M.D., Ph.D., Li Yan, M.D., Ph.D.,
Yunli Xing, M.D., Ph.D., Haili Shi, M.D., Shuyan Li, M.D., Ph.D., Yanxia Liu, M.D., Fan
Liu, M.D., Mei Feng, M.D., Yundai Chen, M.D., Ph.D., Gregory Y.H. Lip, M.D., Ph.D.,
On behalf of the MAFA II investigators

PII: S0735-1097(19)36365-X

DOI: <https://doi.org/10.1016/j.jacc.2019.08.019>

Reference: JAC 26529

To appear in: *Journal of the American College of Cardiology*

Received Date: 28 July 2019

Revised Date: 10 August 2019

Accepted Date: 19 August 2019

Please cite this article as: Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, Yan L, Xing Y, Shi H, Li S, Liu Y, Liu F, Feng M, Chen Y, Lip GYH, On behalf of the MAFA II investigators, Mobile Health Technology for Atrial Fibrillation Screening Using Photoplethysmography-Based Smart Devices: The HUAWEI Heart study, *Journal of the American College of Cardiology* (2019), doi: <https://doi.org/10.1016/j.jacc.2019.08.019>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Mobile Health Technology for Atrial Fibrillation Screening Using Photoplethysmography-Based Smart Devices: The HUAWEI Heart study

Yutao Guo, M.D., Ph.D.1, Hao Wang, M.D., Ph.D.1, Hui Zhang, M.D.1, Tong Liu, M.D., Ph.D.3, Zhaoguang Liang, M.D., Ph.D.4, Yunlong Xia, M.D., Ph.D.5, Li Yan, M.D., Ph.D.6, Yunli Xing, M.D., Ph.D.7, Haili Shi, M.D.8, Shuyan Li, M.D., Ph.D.9, Yanxia Liu, M.D.10, Fan Liu, M.D.11, Mei Feng, M.D.12, Yundai Chen, M.D., Ph.D.1, Gregory Y H Lip, M.D., Ph.D.2, On behalf of the MAFA II investigators.

1: Institutional Affiliations a Chinese PLA General Hospital, Beijing, China; 2: Liverpool Centre for Cardiovascular Sciences, University of Liverpool, Liverpool, United Kingdom; and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 3: Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China; 4: The First Affiliated Hospital of Haerbing Medical University, Haerbing, China; 5: The First Affiliated Hospital of Dalian Medical University, Dalian, China; 6: Yunnan Cardiovascular Hospital, Kunming, China; 7: Beijing Friendship Hospital, Capital Medical University, Beijing, China; 8: Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China; 9: The First Hospital of Jilin University, Changchun, Jilin, China; 10: General Hospital of Shenyang Military, Shenyang, China; 11: The Second Hospital of Hebei Medical University, Shijiazhuang, China; 12: Shanxi Da hospital, Taiyuan, China

Acknowledgments: Our sincere thanks to the HUAWEI Heart Health Research Team for the development and optimization of PPG algorithm, headed by Mr. Xiaoxiang He. Team members include Jiabing Yan, Wenjuan Chen, Qin Chen, Jie Zhang, Xi Huang, and Hongbao Li. Funding: This research project was funded by the National Natural Science Foundation of China (H2501) and was funded by the Health and Family Planning Commission of Heilongjiang Province, China (2017-036), and partly supported by the NIHR Global Health Research Group on Atrial Fibrillation management at the University of Birmingham, UK. Disclosures: GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseeon and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. Other authors: None declared. **MAFA II Investigators:** See Online Appendix. Screenshots of App consent and data privacy; and Verification reports of the algorithm and smart devices are shown in Supplementary Online Figure 7, 8, 10, 11.

Corresponding Authors:

Yundai Chen, MD, PhD
Chinese PLA General Hospital
Department of Cardiology
No.28, Fuxin Road
Beijing, 100853 China
Telephone: + 8618610530521
Fax:0086-55499311 or
E-mail: cyundai@vip.163.com

Gregory YH Lip, MD, PhD
Liverpool Centre for Cardiovascular Science
William Henry Duncan Building
West Derby Street
Liverpool, Merseyside L7 8TX United Kingdom
Telephone: 0151-794-9020
E-mail: gregory.lip@liverpool.ac.uk

Abstract

Background: Low detection and nonadherence are major problems in current management approaches for patients with suspected atrial fibrillation (AF). Mobile health (mHealth) devices may enable earlier AF detection, and improved AF management.

Objectives: To investigate the effectiveness of AF screening in a large population-based cohort using smart device based photoplethysmography (PPG) technology, combined with a clinical care AF management pathway using a mHealth approach.

Methods: AF screening was performed with smart devices using PPG technology (Huawei Technologies Co., Ltd., Shenzhen, China) which were made available for the population aged over 18 years across China. Monitoring for at least 14-days with a wristband (HONOR BAND 4) or wristwatch (HUAWEI WATCH GT, HONOR WATCH), was allowed. The patients with 'possible AF' episodes using the PPG algorithm were further confirmed by health providers among the MAFA (mobile AF App) Telecare center and network hospitals, with clinical evaluation, electrocardiogram (ECG), or 24-h Holter.

Results: There were 246,541 individuals who downloaded the PPG screening App, and 187,912 individuals used smart devices to monitor their pulse rhythm between October 26, 2018 and May 20, 2019. Among those with PPG monitoring (mean age 35 years, 86.7% male), 424 (mean age 54 years, 87.0% male) received a 'suspected AF' notification (424/187,912, 0.23%). Of those effectively followed up, 227 individuals (227/262, 87.0%) were confirmed as having AF, with the positive predictive value (PPV) of PPG signals being 91.6% (95% confidential interval (CI) 91.5%-91.8%). Both 'suspected AF' and 'identified AF' markedly increased with age (p for trend <0.001), and individuals in Northeast China had the highest proportion of detected AF of 0.28% (95%CI 0.20-0.39). Of the individuals with identified AF, 216 (216/227, 95.1%) subsequently entered a programme of integrated AF management using a mobile AF application (mAFA); approximately 80% of 'high risk' patients were successfully anticoagulated.

Conclusions: Based on the present study, continuous home-monitoring with smart device based PPG technology could be a feasible approach for AF screening. This would help efforts at screening and detection of AF, as well as early interventions to reduce stroke and other AF-related complications.

Condensed Abstract: The study aimed to determine the feasibility of AF screening in a large population-based cohort using smart device based photoplethysmography (PPG) technology, combined with a clinical care AF management pathway. There were 187,912 individuals used smart devices to monitor their pulse rhythm between October 26, 2018 and May 20, 2019. 87.0% were confirmed as having AF, with the PPV of PPG signals being 91.6%. Following entry into a programme of integrated AF management using a mobile AF application, approximately 80% of high risk patients were successfully anticoagulated. Based on the present study, continuous home-monitoring with smart device based PPG technology could be a feasible approach for AF screening. This would help efforts at screening and detection of AF, as well as early interventions to reduce stroke and other AF-related complications.

Keywords: atrial fibrillation, screening, photoplethysmography, integrated care

Abbreviations:

AF = atrial fibrillation

ECG = electrocardiogram

PPG = photoplethysmography

USPSTF = US Preventive Services Task Force

mAF App = mobile atrial fibrillation application

PPV = positive predictive value

CHA₂DS₂-VASc = congestive heart failure, hypertension, age ≥ 75 , diabetes, stroke, vascular disease, age 65–74, and sex category (female)

HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly, drugs/alcohol concomitantly

SAMe-T₂T₂R = sex female, age, medical history, treatment, tobacco use, race

Journal Pre-proof

Introduction

Low detection and nonadherence are major problems in current management approaches for patients with suspected atrial fibrillation (AF). AF screening has been advocated with the recognition that this could ultimately reduce AF-related stroke and death, with the initiation of treatments such as oral anticoagulation, and other risk-factor modifications to reduce AF-related complications and arrhythmia progression [1]. Indeed, active screening strategies could improve detection of AF in comparison with routine care. Nonetheless, a systematic screening strategy for AF did not show an obvious advantage to opportunistic screening, using pulse palpation and a 12-lead electrocardiogram (ECG) [2].

Recent advances in mobile and wearable devices provide a possible solution [3]. New technology has been developed to improve the early detection of AF and among these, photoplethysmography (PPG) and single lead ECG recordings are promising methods available to the public for detecting AF [4]. In the STROKESTOP study, a handheld ECG recorder for intermittent ECG recordings over 2 weeks improved AF diagnosis in high-risk population aged 75-76 years old [5]. Another AF screening approach with twice-weekly single-lead ECG recorders among those aged over 65 years identified more incident AF than routine care, but adverse clinical events (including stroke, thromboembolism, death, etc.), were not significantly different over a 52-week follow-up period [6]. Hence, it has been questioned how AF screening could have a more beneficial effect on subsequent AF management, and the U.S. Preventive Services Task Force (USPSTF) recently concluded that the current evidence was insufficient to assess the balance of benefits and harms of screening for atrial fibrillation with ECG [7]. Similarly, current U.K. National Screening Committee policy recommends that population screening for AF should not be offered by the National Health Service [8]. Thus, more evidence

on strategies for improving AF screening, detection and subsequent management to reduce AF-related adverse outcomes is needed.

Approaches using random brief ECG screening could possibly miss those individuals with a low burden of (paroxysmal) AF, and long-term continuous screening may overcome the problem. An ECG skin adhesive patch, which could provide 14-day monitoring, resulted in a higher proportion of AF diagnosis compared with delayed monitoring; however, nearly one third of subjects refused to use the ECG patch, and some individuals reported skin irritation, resulting in early discontinuation structured management [9]. A smartwatch strap with single ECG sensor may be a more comfortable method, with 93% sensitivity and 84% specificity of AF diagnosis compared to a 12 lead ECG, but only 66% of monitored signals could be interpretable with the app algorithm alone [10]. Thus, the stability of the signal quality and motion artifacts are additional considerations when considering an ECG-based approach to AF screening.

In contrast, increasing evidence supports PPG-monitoring for AF screening [11,12,13]. Mass screening for AF has been carried out using smartphone cameras with reliable PPG signals [14]. In our previous pilot study, both smartphones and smart bands with PPG demonstrated good performance in detecting AF [15]. Hence, it may be more practical to screen for AF in a large population using a PPG-based smart device, especially if integrated with a structured management program for AF, again based on smart technology. In a pilot study of such a structured management program, we showed that a mHealth technology-supported AF application (mAF App) could be developed and validated, integrating patient clinical decision support tools, guideline-based treatment, educational materials and patient involvement strategies with self-care protocols and structured follow-up [16].

In the Huawei Heart Study, our aim was to screen for AF and report the incidence of AF identified, as well as the proportion of AF patients being anticoagulated. We hypothesized that use of a mobile health PPG technology approach would facilitate AF screening, and the associated App-based integrated AF care approach would result in early AF detection and increased use of oral anticoagulation. The latter could have the potential in reducing AF-related complications such as stroke and mortality [17].

Methods

The Mobile health technology for improved screening, patient involvement and optimizing integrated care in Atrial Fibrillation (MAFA II) study program was developed to verify a screening and integrated care approach to improving AF management. The ‘Pre-MAFA’ study was the first stage of the MAFA II program, using HUAWEI smart technology (herein referred to as the ‘Huawei Heart Study’) to test the feasibility of continuous home-monitoring with PPG technology in a large population [18] (Online Figure 1). Identified AF patients were then transferred into a structured program of holistic and integrated care using a smartphone App (mAF App) [18]. The present report only focuses on the ‘Huawei Heart Study’, which is the AF screening component (‘Pre-MAFA’) of this programme.

AF screening with smart devices using PPG technology (Huawei Technologies Co., Ltd., Shenzhen, China) were made available for the population aged over 18 years across China. Inclusion criteria included use of the Huawei phone (Android 5.0 or higher), and one of following smart devices: Huawei Watch GT (Version 1.0.3.52 or higher), Honor Watch (Version 1.0.3.52 or higher), and Honor Band 4 (Version 1.0.0.86 or higher). The participants needed to have compatible HUAWEI smart device(s) and phone. Exclusion criteria included age <18 years, and inability to use smart phone or devices. At least 14-day monitoring with smart devices based

on PPG (with the PPG algorithm developed by Huawei) was proposed. The study was approved by the Central Medical Ethic Committee of Chinese PLA General Hospital (Approval number: S2017-105-02) and registered at the Chinese Clinical Trial Registry (ChiCTR) website (ChiCTR-OOC-17014138). Subjects could freely download the app in the HUAWEI Appstore. All subjects who were interested in the study were informed of the study design and gave their informed consent before entering the study. Adults downloading the AF screening App across China mainland were enrolled into present Pre-MAFA study analysis between October 26, 2018 to May 20, 2019.

AF detection

An AF screening App was developed based on the Android Operating System (Google, Mountain View, California). The individuals could initiate rhythm monitoring with AF screening App using smart devices. The users could also start directly AF detection with MAFA (**Figure 1**). The irregular pulse wave would be screened with active or periodic measuring using the PPG algorithm. Individuals could initiate active measurements at rest, and 45-second PPG signals would be collected. Periodic measurements would be automatically be taken every 10 minutes, and 60-second PPG signals would continuously be collected. The discrimination rule of the PPG algorithm and notification of ‘suspected AF’ is shown in **Figure 2**. A notification of ‘suspected AF’ would be delivered, once the proportion of ‘possible AF’ episodes was 100%, when ten measurements were initiated. In the case of PPG measurements >10 , the threshold T was set to ensure that the positive predictive value of making a decision was over 0.85, and the sensitivity would be as high as possible. The T could be adjusted to a more suitable value with enough study data were collected. The notification of ‘suspected AF’ would also be delivered once the

proportion of ‘possible AF’ episodes over threshold T in the setting of PPG measurements was >10 (**Figure 2**).

AF diagnosis and management

The individuals with ‘suspected AF’ episodes using the PPG algorithm were further confirmed by the health providers using the MAFA Telecare center and network hospitals, with clinical evaluation, ECG, or 24-h Holter (Online Figure 2). Individuals with ‘identified AF’ would be managed according to an App-based AF integrated care pathway approach, based on the ABC (‘A’ Avoid stroke, ‘B’ Better symptom management, and ‘C’ Cardiovascular risk and comorbidity management) pathway [19]. The ABC pathway approach has been associated with improved clinical outcomes in various independent cohorts [20,21,22].

Statistical analysis

Continuous variables were tested for normality by the Kolmogorov-Smirnov test. Data with a normal distribution were presented as a mean (standard deviation, SD). Data with a non-normal distribution were presented as median (interquartile range, IQR) and were analyzed by using Kruskal-Wallis test. χ^2 test was used for categorical variables. Data visualization analysis was utilized for the enrollment across China with ECharts, version 4.2.1 (Apache Software Foundation).

The “irregular pulse rhythm” by PPG algorithm was observed, and the predictive ability of AF with PPG algorithm was analyzed in comparison with the confirmed diagnosis of AF using clinical evaluation, ECG, or 24-h Holter by the health providers from the MAFA Telecare center and network hospitals. The proportion of "identified" AF from the general population screening that were enrolled into the subsequent main MAFA integrated care trial was calculated to explore the feasibility of the approach AF screening combined with integrated care.

The monitoring method for first “suspected” AF was calculated, and “suspected” AF episodes in relation to measurement method, the automatic periodical measurements and active measurements, were analyzed using the Kruskal-Wallis test for the comparisons among different measurement approaches. Moreover, the influence of the continuous monitoring time on first detected “suspected” and “identified” AF episodes were investigated, to explore the optimal screening “window”. Incident AF was analysed in relation to age strata, sex, and region. Finally, AF management among individuals with “identified” AF enrolled into an App-based AF integrated care structured programme with the mAFA trial, were investigated, including their stroke risk, bleeding risk, and the likelihood for good anticoagulation control. Anticoagulant use classified by risk assessment is reported, while the changes on oral anticoagulant use among different risk strata were compared.

A 2-sided P-value <0.05 was considered as statistically significant. The 95% confidential intervals (CIs) were calculated with Wilson score method without continuity correction [18]. Statistical analysis was performed using IBM SPSS Statistics, version 25.0 (SPSS Inc.).

Results

There were 246541 individuals who downloaded the PPG screening app, and 187912 individuals used smart devices to monitor their pulse rhythm between October 26, 2018 and May 20, 2019. Enrollment and baseline characteristics are summarized in Online Figure 3 **and Table 1**.

Monitoring method and identification

There were 265,139 ‘suspected AF’ episodes for 424 subjects (mean age 54 years, 87.0% male) among 187,912 subjects screened (mean age 35 years, 86.7% male). Of the ‘suspected AF’ subjects, 262 (262/424, 61.8%) were effectively followed up with full medical history, physical

examination, ECG, or 24-hour Holter (**Figure 3**). Of those with full assessment, 227 (227/262, 87.0%) subjects were confirmed as having AF. Cardiac rhythms of ‘suspected AF’ episodes are summarized in Online Figure 4.

There were 186,956 ‘identified AF’ episodes for the 227 subjects and 203,985 episodes for the 262 ‘suspected AF’ subjects. The positive predictive value (PPV) of PPG signals was 91.6% (95%CI 91.5%-91.8%). Individuals with ‘suspected AF’ episodes were mostly monitored using automatic periodical measurements (periodical vs. active measurements, 37.0% vs. 7.6%, $p<0.001$) (Online Figure 5, Online Table 1). 70.8% of AF episodes were found within 14 days, but nearly one third of AF episodes were recorded after two weeks (**Figure 4**). The distribution of monitoring time in the whole cohort is shown in Online Figure 9. Supplementary material online summarizes user reported adverse events (Online Table 2), a comparison performance of the various smart devices utilized in PPG screening (Online Table 3), and the standby time of the various smart devices with or without PPG screening (Online Table 4). They show generally high specificity (approx. 99%), sensitivity (100%) and accuracy (>99%), irrespective of smart device used.

AF episodes in the general population

Incident ‘suspected AF’ and ‘identified’ AF markedly increased with age (p for trend <0.001) (**Figure 5**). The highest proportion of AF episodes was among the elderly, ie. those aged over 65 years, with 2.78% (95% CI 2.28-3.38) being ‘suspected AF’, and 1.70% (1.31-2.19) being ‘identified’ AF (**Figure 5**). There was a higher risk of incident AF in individuals aged over 55 years compared to those aged under 55 years (2.62% vs 0.17%; $p<0.001$). The prevalence of detected AF was highest in Northeast China compared to other regions in China ($p<0.001$, Online Figure 6).

AF management

216 (216/227, 95.1%) individuals with ‘identified AF’ were entered into an App-based AF integrated care structured program with MAFA (**Figure 3**); of these, 29 (29/216, 13.42%) who initiated MAFA to monitor the rhythm were subsequently found to have a known AF diagnosis. Clinical decision support tools were provided for doctors and patients (Online Table 5). The patient’s personalized stroke risk was assessed with the CHA2DS2-VASc score (mean, SD, 1.07, 1.09), while bleeding risk was assessed using the HAS-BLED score (mean, SD, 0.35, 0.52), respectively. Their likelihood for good anticoagulation control was assessed using the SAMe-T2T2R score (mean, SD, 3.71, 0.66). Distribution of subjects according to these scores are shown in Online Table 5.

Overall, 79.6% of patients at high-risk were anticoagulated (Table 3). There was no difference in risk characteristics and anticoagulant use among high-risk individuals comparing individuals with newly detected AF and with known AF (Table 2).

Discussion

In the Huawei Heart Study, we show that PPG-based smart devices were feasible as an easy-to-use screening tool in this population-based, large-scale AF screening study, with a good performance for AF detection (**Central Illustration**). Second, the heterogeneity of incident AF, in relation to regions and age, suggests the need for a different prevention approaches based on local population requirements. Thus, the use of mobile and wearable devices could provide a simple, feasible and practical mHealth approach for AF early detection, that can be followed by guideline-guided app-based intervention.

AF management integrated with AF detection might provide more benefits for patients. Previous studies have demonstrated that smart devices (smartphone, E-patch, handing device,

wrist band, etc.) can be used for AF detection [5,6,9,10,11,12,13,14,15]; however, an integration with subsequent clinical management of 'screened AF' was lacking. In the present Huawei Heart Study (Pre-MAFA), 95.1% of individuals with identified AF, who screened from general population, were entered into an AF integrated care program with MAFA, providing guideline-guided intervention and leading to a high proportion of patients being successfully anticoagulated.

The clinical decision support within the MAFA program with CHA₂DS₂-VASc, HAS-BLED, and SAME-TT₂R₂ scores on the MAFA platform provides risk-assessment advice for doctors, and facilitates sharing decision making for the patients. In this study, approximately 80% of 'high risk' AF patients in MAFA received oral anticoagulants (OACs), which is a marked improvement over prior reports of suboptimal thromboprophylaxis in prior Chinese cohorts [23,24,25]. Thus, AF screening, combined with a clinical integrated care program for detected AF, may translate to better treatment and prevention of AF-related major complications, such as stroke and death.

The continuity, comfort and the stability of monitoring signals, that are not influenced by motion, are challenges for a good predictive ability for AF using smart devices. A lower accuracy in ambulatory than sedentary patients has been observed with a Cardiogram app using a wristwatch [26]. Indeed, only 66% of monitoring signals could be interpretable with a single-lead ECG wristwatch by App algorithm alone [10]. In the present study, 91.6% of PPG positive signals by algorithm were confirmed as AF. The improved screening ability of AF with the present PPG-based smart devices possibly stems from frequent, continuous monitoring and the good quality of monitoring signals. With a single battery life (average standby time with HUAWEI smart devices is 6.7 days with PPG screening), periodic measurements could be taken

automatically every 10 minutes in this study, which was far more frequent than obtained from the Apple watch in the Apple Heart Study, with measurements only taken every two hours at baseline, which was then increased to every 16 minutes once an irregular tachogram was detected [27]. In addition, the discrimination of the PPG algorithm could possibly contribute to the better detection of AF, as shown in this study.

Our study found that most AF episodes were found within 14 days, but nearly one third of AF episodes were detected on monitoring after 2 weeks. In the case of paroxysmal AF, the time to the first detection has been inversely related to AF burden [28,29]. Automatic periodic PPG measurements have the advantage of active measurements in the search for AF episodes in this study, suggesting that a continuing monitoring approach was better than single-point intermittent monitoring. Our study also supports the possibility that PPG-based wrist-worn wearables (watches, bands) would be the good choices for AF screening [30,31].

In this study, the prevalence of ‘suspected AF’ of 0.2% in the general population was lower than the 0.5% reported in Apple Heart Study [27]. There are possibly several reasons for this. This was much younger population with 1.8% who were aged over 65 years old in the present study, compared to 6% being aged over 65 years old in Apple Heart Study [27]. There is also a lower incidence and prevalence of AF in the Chinese population compared to the Western population [32,33]. The strict discrimination rule of the PPG algorithm may also contribute to the low prevalence of detected AF.

However, a trend for increasing detected AF with aging was evident in the Chinese population, with a fifteen-fold (2.62/0.17) greater AF risk in those aged >55 years compared to those aged < 55 years; this difference was only eight-fold (4.5/0.53) in the Apple Heart Study. AF screening might be much more beneficial for those at high-risk of AF, (e.g., population with

age >55 years). The cost effectiveness of AF screening related to different population risks would need to be ascertained in future studies. In addition, we noted a geographical difference in incident AF in the present study, with the highest prevalence of AF in Northeast China that was consistent with the distribution of clinical risk factors for AF (Online Table 6). The heterogeneity of risk factors incident AF may suggest the need for different prevention approaches in different settings based on local clinical risk profiles.

Strengths and limitations

There were several limitations in this study. We were not doing a trial of the efficiency of AF screening since the current study relates to the "yield" with the current technology and the specificity of the diagnosis, rather than sensitivity. Although we had strict follow-up procedures for 'suspected AF', there were 38% of individuals with 'suspected AF' who could not be effectively followed up, which would decrease the proportion of identified AF. For the PPV calculation with PPG signals, we did not have real-time 12-lead ECG data synchronized with PPG-based smart devices. Indeed, it would be difficult to make all individuals have a 14-day 12-lead Holter examination with a mass population screening study. However, the diagnosis of AF was confirmed with medical history, physical examination, ECG or 24-Holter by healthcare providers. While we aimed to focus on newly diagnosed or detected AF, 29 subjects were subsequently found to have known AF, as was also seen in the Apple Heart Study, where 15% with known AF entered that study [27]. Also, incident AF detection in present study might be impacted by the availability of smart phones and devices. In the present study, 24% of subjects downloaded the App but were without compatible smart devices. The underlying reason(s) may be multifactorial; however, 187,912 individuals were entered into the study, suggested the PPG-based smart device could still be a feasible screening strategy. Finally, we did not report on hard

outcomes (stroke, death, etc) impacted with AF screening approach in the present Pre-MAFA study and would be further reported in the future from the ongoing MAFA II trial [18].

Conclusion

Continuous home-monitoring with smart device-based PPG technology is a feasible approach for screening and early detection of AF in a large population. This could help efforts at screening and detection of AF, as well as early interventions to reduce stroke and other AF-related complications.

Perspectives

COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS: We demonstrate the feasibility of AF screening in a large population-based cohort using smart device based photoplethysmography (PPG) technology, combined with a clinical care AF management pathway. Following entry into a program of integrated AF management using a mobile AF application, approximately 80% of high-risk patients were successfully anticoagulated.

TRANSLATIONAL OUTLOOK: Continuous home-monitoring with smart device-based PPG technology could be a feasible approach for AF screening. This would help efforts at screening and detection of AF, as well as early interventions to reduce stroke and other AF-related complications. This integrated approach should be verified in randomized trials.

References

1. Mairesse GH, Moran P, Van Gelder IC, et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología. *Europace* 2017;19:1589–1623.
2. Fitzmaurice DA, McCahon D, Baker J, et al. Is screening for AF worthwhile? Stroke risk in a screened population from the SAFE study. *Fam Pr* 2014;31:298–302.
3. McConnell MV, Turakhia MP, Harrington RA, King AC AE. Mobile Health Advances in Physical Activity, Fitness, and Atrial Fibrillation: Moving Hearts. *J Am Coll Cardiol* 2018;71:2691–2701.
4. Kotecha D, Breithardt G, Camm AJ, et al. Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. *Europace* 2018;20:395–407.
5. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V RM. Mass Screening for Untreated Atrial Fibrillation The STROKESTOP Study. *Circulation* 2015;131:2176–2184.
6. Halcox JPJ, Wareham K, Cardew A, et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study. *Circulation* 2017;136:1784–1794.
7. US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for Atrial Fibrillation With Electrocardiography: US Preventive Services Task Force Recommendation Statement. *JAMA* 2018;320:478–484.
8. UK National Screening Committee. Screening for Atrial Fibrillation in the over 65s. London: UK National Screening Committee; June 2014.

9. Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial. *JAMA* 2018;320:146–155.
10. Bumgarner JM, Lambert CT, Hussein AA, et al. Smartwatch Algorithm for Automated Detection of Atrial Fibrillation. *J Am Coll Cardiol* 2018;71:2381–2388.
11. Tang SC, Huang PW, Hung CS, et al. Identification of Atrial Fibrillation by Quantitative Analyses of Fingertip Photoplethysmogram. *Sci Rep* 2017;7:45644.
12. Krivoshei L, Weber S, Burkard T, et al. Smart detection of atrial fibrillation? *Europace* 2017;19:753–757.
13. Poh MZ, Poh YC, Chan PH, et al. Diagnostic assessment of a deep learning system for detecting atrial fibrillation in pulse waveforms. *Heart* 2018;104:1921–1928.
14. Verbrugge FH, Proesmans T, Vijgen J, et al. Atrial fibrillation screening with photoplethysmography through a smartphone camera. *Europace* 2019; May 5. pii: euz119.
15. Fan YY, Li YG, Li J, et al. Diagnostic Performance of a Smart Device With Photoplethysmography Technology for Atrial Fibrillation Detection: Pilot Study (Pre-mAFA II Registry). *JMIR Mhealth Uhealth* 2019;7:e11437.
16. Guo Y, Chen Y, Lane DA, Liu L, Wang Y, Lip GYH. Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. *Am J Med* 2017;130:1388-1396.e6.
17. Lip GYH, Freedman B, De Caterina R PT. Stroke prevention in atrial fibrillation: Past, present and future. *Thromb Haemost* 2017;117:1230–1239.

18. Guo Y, Lane DA, Wang L, et al. Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAF-App) II randomised trial. *Int J Clin Pr* 2019;Apr 19:e13352.
19. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. *Chest* 2018;154:1121–1201.
20. Proietti M, Romiti GF, Olshansky B, Lane DA LG. Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. *Am J Med* 2018;131:1359-1366.e6.
21. Pastori D, Pignatelli P, Menichelli D, Violi F LG. Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort. *Mayo Clin Proc* 2019;94:1261–1267.
22. Yoon M, Yang PS, Jang E, et al. Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study. *Thromb Haemost* 2019;July 2. doi: 10.1055/s-0039-1693516.
23. Guo Y, Pisters R, Apostolakis S, et al. Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact? *Int J Cardiol* 2013;168:515–522.
24. Guo Y, Wang H, Tian Y, Wang Y, Lip GYH. Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. *Chest* 2015;148:62–72.

25. Chao TF, Chiang CE, Lin YJ, et al. Evolving Changes of the Use of Oral Anticoagulants and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation in Taiwan. *Circulation* 2018;138:1485–1487.
26. Tison GH, Sanchez JM, Ballinger B, et al. Passive Detection of Atrial Fibrillation Using a Commercially Available Smartwatch. *JAMA Cardiol* 2018;3:409–416.
27. Hughes S. Apple Watch Helps Detect AF: Is This the Future? *Medscape*. 2019. p. March 6. https://www.medscape.com/viewarticle/910509#vp_3
28. Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic Utility of a Novel Leadless Arrhythmia Monitoring Device. *Am J Cardiol* 2013;112:520–524.
29. Solomon MD, Yang J, Sung SH, et al. Incidence and timing of potentially high-risk arrhythmias detected through long term continuous ambulatory electrocardiographic monitoring. *BMC Cardiovasc Disord* 2006;17:35.
30. Hochstadt A, Chorin E, Viskin S, Schwartz AL, Lubman N RR. Continuous heart rate monitoring for automatic detection of atrial fibrillation with novel bio-sensing technology. *J Electrocardiol* 2019;52:23–27.
31. Bonomi AG, Schipper F, Eerikäinen LM, et al. Atrial Fibrillation Detection Using a Novel Cardiac Ambulatory Monitor Based on Photo-Plethysmography at the Wrist. *J Am Hear Assoc* 2018;7:e009351.
32. Guo Y, Tian Y, Wang H, Si Q, Wang Y, Lip GYH. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. *Chest* 2015;147:109–119.

33. Lip GYH, Brechin CM L DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. *Chest* 2012;142:1489–1498.

Journal Pre-proof

Figure Legends

Figure 1: AF screening flow diagram. *MAFA: mobile Atrial Fibrillation Application.

Figure 2: The notification of “suspected” AF by algorithm. * $N > 10$, $0 < T < 1$, seen AF detection in the Method in the text.

Figure 3: AF screening, confirmation, and transference into MAFA. Inclusion: Adult ≥ 18 years; Huawei phone (Android 5.0 or higher); Smart devices: Huawei Watch GT (Version 1.0.3.52 or higher), Honor Watch (Version 1.0.3.52 or higher), Honor Band 4 (Version 1.0.0.86 or higher). Exclusion: Adult < 18 years; Inability to use smart phone or devices.

Figure 4: Monitoring time to first AF episode. The monitoring time to first detected AF episode were classified by 0-7 days, 8-14 days, 15-21 days, 22-30 days, and > 31 days.

Figure 5: Incident “suspected” and “identified” AF among 187,912 population. The incident "suspected" and "identified" AF were shown in relation to age- and sex-proportions.

Central Illustration: Mobile health devices could be a feasible approach for AF screening, and into subsequent AF integrated management. MAFA: mobile Atrial Fibrillation Application.

Table 1: Baseline characteristics.

	Overall Cohort (n=187,912)	Notification (n=424)	Individuals with clinical evaluation (n=262)	Identified AF (n=227)
Suspected AF episodes, n	265,139	265,139	203,985	186,956
Female, n (%)	24938 (13.3)	55(13.0)	43(16.4)	42(18.5)
Age, mean (SD)	34.7(11.5)	54.1(14.3)	54.9(14.0)	56.1(13.7)
≥ 65 , n (%)	3419 (1.8)	95(22.4)	62(23.7)	58(25.5)
55-64, n (%)	7491 (4.0)	112(26.4)	71(27.1)	69(30.4)
40-54, n (%)	44432 (23.6)	136(32.1)	82(31.3)	64(28.2)
20-39, n (%)	132570 (70.5)	81 (19.1)	47(17.9)	36(15.9)
Location				
East China, n (%)	57,177 (30.4)	116 (27.4)	67 (25.6)	58 (25.6)
North China, n (%)	32,488 (17.3)	98 (23.1)	71 (27.1)	63 (27.8)
Central China, n (%)	26,033 (13.9)	42 (9.9)	25 (9.5)	19 (8.4)
South China, n (%)	21,333 (11.4)	36 (8.5)	23 (8.8)	20 (8.8)

Southwest China, n (%)	17,156 (9.1)	30 (7.1)	15 (5.7)	13 (5.7)
Northwest China, n (%)	12,762 (6.8)	30 (7.1)	15 (5.7)	14 (6.2)
Northeast China, n (%)	12,805 (6.8)	62 (14.6)	42 (16.0)	36 (15.9)
Others, n (%)	8,158 (4.3)	10 (2.4)	4 (1.5)	4 (1.8)

Table 2: Risk assessments and anticoagulant use of the 216 patients entered into the MAFA programme.

	Individuals with newly detected AF (n=187)	Individuals with known AF (n=29)	p
CHA ₂ DS ₂ -VASc score			
(mean, SD)	1.04(1.05)	1.24 (1.35)	0.365
(median, interquartile range)	1(0-2)	1(0-2)	
HAS-BLED score			
(mean, SD)	0.33(0.52)	0.48(0.57)	0.141
(median, interquartile range)	0(0-1)	0(0-1)	
SAMe-T ₂ T ₂ R score			
(mean, SD)	3.72 (0.63)	3.66 (0.85)	0.644
(median, interquartile range)	4(3-4)	4(3-4)	
*Individuals at high risk (n,%)	46 (24.60)	8 (27.59)	0.730
Anticoagulant use amongst patients at high risk	35(76.09)	8 (100%)	0.266

* Individuals at high risk: CHA₂DS₂-VASc ≥ 3 in females, ≥ 2 in males.

See Figure 3 for patient flow.

Journal Pre-proof

Table 3: Oral anticoagulant use in AF patients.

	Low risk	Intermediate risk	High risk
N (%)	91 (42.1)	71(32.9)	54 (25.0)
Anticoagulant use at baseline, n%	5 (5.49)	9 (12.68)	43 (79.63)
Anticoagulant use at 3 months, n%	3 (3.30)	29 (40.85)	42 (77.78)
p	0.372	<0.001	0.673

* Low risk: CHA₂DS₂-VASc of 0 in males, or 1 in females; Intermediate risk: CHA₂DS₂-VASc of 2 in female, 1 in male; High risk: CHA₂DS₂-VASc ≥ 3 in females, ≥ 2 in males. McNemar's test was used for testing the difference.

The reasons for patients with or without oral anticoagulants (OACs) on baseline:

- Low risk patients with OACs at baseline: 2 patients undergoing AF ablation, with OAC used after discharge, 2 patients with current onset acute AF episodes, and 1 patient with rheumatic valvular heart disease.
- High risk patients without OACs at baseline: six patients who were unwilling to accept anticoagulants, four patients with antiplatelets (aspirin or clopidogrel), and one patient anticoagulated with traditional Chinese medicine.




Figure 1 AF screening flow diagram

*MAFA: mobile Atrial Fibrillation Application




Figure 2 The notification of "suspected" AF by algorithm * $N > 10$, $0 < T < 1$, See AF detection in the Method in the text.

InclusionAdult ≥ 18 years

Huawei phone (Android 5.0 or higher)

Smart devices:

Huawei Watch GT (Version 1.0.3.52 or higher)

Honor Watch (Version 1.0.3.52 or higher)

Honor Band 4 (Version 1.0.0.86 or higher)

ExclusionAdult < 18 years

Inability to use smart phone or devices




Figure 3 AF screening, confirmation, and transference into MAFA






Figure 4 Monitoring time to first detected AF episode



Figure 5 Incident "suspected" and "identified" AF among the screened population (n=187912)



Incident“suspected”and“identified”AF



Oral anticoagulant use in AF patients with MAFA

	Low risk	Intermediate risk	High risk
N (%)	91 (42.1)	71(32.9)	54 (25.0)
Anticoagulant use at baseline, n%	5 (5.49)	9 (12.68)	43 (79.63)
Anticoagulant use at 3 months, n%	3 (3.30)	29 (40.85)	42 (77.78)
p	0.470	<0.001	0.814

* Low risk: CHA₂DS₂-VASc of 0 in males, or 1 in females; Intermediate risk: CHA₂DS₂-VASc of 2 in female, 1 in male; High risk: CHA₂DS₂-VASc ≥3 in females, ≥2 in males.

CENTRAL ILLUSTRATION:
Mobile health devices could be a feasible approach for AF screening, and into subsequent AF integrated management. MAFA: mobile Atrial Fibrillation Application

SUPPLEMENTARY APPENDIX

Mobile Health technology for atrial fibrillation screening using photoplethysmography-based smart devices: The HUAWEI Heart study

Yutao Guo, M.D., Ph.D.¹, Hao Wang, M.D., Ph.D.¹, Hui Zhang, M.D.¹, Tong Liu, M.D., Ph.D.³, Zhaoguang Liang, M.D., Ph.D.⁴, Yunlong Xia, M.D., Ph.D.⁵, Li Yan, M.D., Ph.D.⁶, Yunli Xing, M.D., Ph.D.⁷, Haili Shi, M.D.⁸, Shuyan Li, M.D., Ph.D.⁹, Yanxia Liu, M.D.¹⁰, Fan Liu, M.D.¹¹, Mei Feng, M.D.¹², Yundai Chen, M.D., Ph.D.¹, Gregory Y H Lip, M.D., Ph.D.², On behalf of the MAFA II investigators.

1: Institutional Affiliations ^a Chinese PLA General Hospital, Beijing, China; 2: Liverpool Centre for Cardiovascular Sciences, University of Liverpool, Liverpool, United Kingdom; and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 3: Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China; 4: The First Affiliated Hospital of Haerbing Medical University, Haerbing, China; 5: The First Affiliated Hospital of Dalian Medical University, Dalian, China; 6: Yunnan Cardiovascular Hospital, Kunming, China; 7: Beijing Friendship Hospital, Capital Medical University, Beijing, China; 8: Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China; 9: The First Hospital of Jilin University, Changchun, Jilin, China; 10: General Hospital of Shenyang Military, Shenyang, China; 11: The Second Hospital of Hebei Medical University, Shijiazhuang, China; 12: Shanxi Da hospital, Taiyuan, China

Corresponding Authors:

Prof. Yundai Chen

Email: cyundai@vip.163.com

Telephone and Fax: 0086-55499311 or

Prof. Gregory Y H Lip

Email: gregory.lip@liverpool.ac.uk

Telephone and Fax: 0151-794-9020

Contents

MAFA II Investigators	p.3
Supplementary results	p.6
...Tables	p.6
...Figures	p.12
Verification report of PPG algorithm	p.21
Verification report of smart devices used	p.22

MAFA II investigators**Executive Steering Committee:**

Yutao Guo	Chinese PLA General Hospital, Beijing, China (Co-Chair)
Gregory Y H Lip	Institute of Cardiovascular Sciences, University of Birmingham, UK; Liverpool Centre for Cardiovascular Science, University of Liverpool, UK (Co-chair)
Deirdre A. Lane	Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom
Yundai Chen	Chinese PLA General Hospital, Beijing, China
Liming Wang	The National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China

Steering committee:

Jens Eckstein	University Hospital Basel, Switzerland
G Neil Thomas	Institute of Applied Health Research, University of Birmingham, United Kingdom
Liu Tong	The Second Hospital of Tianjin Medical University, Tianjin, China
Feng Mei	Shanxi Dayi Hospital, Taiyuan, Shanxi, China
Liu Xuejun	Affiliated First Hospital, Shanxi Medical University, China
Li Xiaoming	Cardiovascular Disease Hospital of Shanxi Province, China
Shan Zhaoliang	PLA General Hospital, Beijing, China
Shi Xiangming	PLA General Hospital, Beijing, China
Zhang Wei	PLA Army General Hospital, Beijing, China
Xing Yunli	Beijing Friendship Hospital, Capital Medical University, Beijing, China
Wen Jing	Beijing Haidian Hospital, Beijing, China
Wu Fan	Tianjin Medical University General Hospital, Tianjin, China
Yang Sitong	The First Affiliated Hospital, Ji Lin University, Ji Lin, China
Jin Xiaoqing	Tongji Hospital, Tongji medical College, Huazhong University Of Science & Technology, Wuhan, China
Yang Bo	Xiangya Hospital Central South University, Changsha, China
Bai Xiaojuan	ShengJing Hospital of China Medical University, Shengyang, China
Jiang Yuting	Suqian Hospital, Jiangsu, China
Liu Yangxia	General Hospital of Shengyang Military, Shengyang, China
Song Yingying	Bozhou Renmin Hospital, Anhui, China
Tan Zhongju	The First Hospital of Zhejiang Province, Hangzhou, China
Yang Li	Yunnan Cardiovascular Hospital, Kunming, China
Luan Tianzhu	The First Affiliated Hospital of Haerbing Medical University, Haerbing, China
Niu Chunfeng	The Second Affiliated Hospital of Haerbing Medical University, Haerbing, China
Zhang Lili	The Fourth Affiliated Hospital of Haerbing Medical University,

	Haerbing, China
Li Shuyan	The First Affiliated Hospital, Ji Lin University, Ji Lin, China
Wang Zulu	General Hospital of Shengyang Military, Shengyang, China
Xv Bing	The First People's Hospital of Shengyang, Shengyang, China
Liu Liming	The Second Affiliated Hospital of Shengyang Medical University, Shengyang, China
Jin Yuanzhe	The Fourth Affiliated Hospital of China Medical University, Shengyang, China
Xia Yunlong	The First Affiliated Hospital of Dalian Medical University, Dalian, China
Chen Xiaohong	The People's Hospital of Liaoning Province, Shengyang, China
Wu Fang	Rui Jin Hospital, Tong university School of Medicine, Shanghai, China
Zhong Lina	The Affiliated Hospital of Qingdao University, Qingdao, China
Sun yihong	China-Japan Friendship Hospital, Beijing, China
Jia shujie	Beijing Anzhen Hospital, Capital Medical University, Beijing, China
Li Jing	Xuanwu Hospital Capital Medical University, Beijing, China
Li Nan	The Third People's Hospital of Dalian, Dalian, China
Li shijun	Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, China
Liu huixia	Guangdong Academy of Medical Sciences Guangdong General Hospital, Guangdong, China
Li Rong	The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China
Liu Fan	The Second Hospital of Hebei Medical University, Hebei, China
Ge qingfeng	North China University Science And Technology Affiliated Hospital
Guan tianyun	The Second Hospital of Jilin University, Jilin, China
Wen Yuan	The Second Affiliated Hospital of Nanchang University, Nanchang, China
Li Xin	BenQ Hospital affiliated to Nanjing Medical University, Nanjing, China
Ren Yan	Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Chen xiaoping	Taiyuan City Central Hospital, Taiyuan, China
Chen ronghua	Tangshan People's Hospital, Tangshan, China
Shi Yun	Tianjin Fourth Central Hospital, Tianjin, China
Zhao yulan	The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Shi haili	Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China
Zhao yujie	Zhengzhou Seventh People's Hospital, Zhengzhou, China
Wang quanchun	Shenyang Fifth People's Hospital, Shenyang, China
Sun weidong	Taian City Central Hospital, Taian, China
Wei Lin	Harbin First Hospital, Harbin, China

Data Safety Monitoring Board:

Esther Chan	The University of Hong Kong, Hong Kong, China
Shan Guangliang	Department of Epidemiology and Statistics, Institute of Basic Medical Sciences, Peking Union Medical College, Beijing, China
Yao Chen	Peking University Clinical Research Institute, Beijing, China
Zong Wei	China Foreign Affairs University, Beijing, China
Chen Dandi	West China School of Public Health, Chengdu, China

Clinical events committee:

Han Xiang	Department of Neurology, Huashan Hospital of Fudan University, Shanghai, China
Xu Anding	Department of Neurology, the First Affiliated Hospital of Jinan University, Guang Zhou, China
Fan Xiaohan	Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China
Yu Ziqiang	Institute of Blood Research of Jiangsu Province, China
Gu Xiang	Department of Cardiology, People's Hospital of Subei, Affiliated Hospital of Yangzhou University, Jiangsu Province, China
Ge Fulin	Department of Gastroenterology, China PLA General Hospital, Beijing, China

Online Table 1 “Suspected” AF episodes in relation to measurement method

	Total subjects with “suspected” AF (n=424)	Subjects with “suspected” AF followed up (n=262)	Subjects identified with AF (n=227)
Active measurement (median, IQR)	172.0 (56.5-396.0)	200.5(53.7-518.7)	210.0 (86.0-518.7)
Automatic periodic measurement (median, IQR)	232.5 (57.5-690.2)	286.0 (66.0-860.0)	319.0 (65.0-900.0)
Active and periodic measurement (median, IQR)	1219.5 (263.7-2092.0)	1427.0(362.0-4416.0)	1430.0 (594.0-4461.0)
P	<0.001	<0.001	<0.001

* IQR: interquartile range.

Kruskal-Wallis test was used for the comparison among different measurement approaches.

When the subjects downloaded App and had matched smart devices, periodic measurements were automatically taken every 10 minutes, and 60-second PPG signals would be continuously collected, per measurement. In addition, subjects could initiate (additional) active measurements as needed.

Online Table 2 Users reported adverse events

	Overall cohort
Total	186
Any device connection and data synchronization issues	123
Login and experience issues (any)	63
Skin irritation, anxiety, pressure	0

Online Table 3 Comparison of the performance of smart devices utilized in PPG screening

Smart devices	Planned enrolled subjects	Enrolled subjects	AF	Sinus rhythm	Specificity	Sensitivity	Accuracy
HONOR BAND 4	200	264	27	237	99.2%	100%	99.2%
HONOR WATCH	200	265	24	241	99.2%	100%	99.2%
HUAWEI WATCH GT	200	212	22	190	98.9%	100%	99.1%

Online Table 4: Comparison of the standby time of smart devices with or without PPG screening

Smart devices	Battery(mAh)	Standby time without PPG screening (days)	Standby time with PPG screening (days)
HUAWEI WATCH GT	420	30	12
HONOR WATCH	178	14	5.5
HUAWEI BAND 3/3PRO	100	12	4.5
HONOR BAND 4/5	100	14	5

OnlineTable 5: Clinical decision support for 216 identified AF entering the MAFA programme


Risk scores	n	%
CHA₂DS₂-VASc		
0	81	37.5
1	69	31.9
2	45	20.8
3	14	6.5
4	5	2.3
5	2	.9
HAS-BLED		
0	146	67.6
1	66	30.6
2	3	1.4
3	1	.5
SAMe-T₂T₂R		
2	6	2.8
3	69	31.9
4	124	57.4
5	16	7.4
6	1	.5
Total	216	100

OnlineTable 6 Risk factors of 66573 individuals with C2HEST scores


	East China (n=20095)	North China(n=11574)	South China (n=9224)	Central China (n=7651)	Southwest China (n=6077)	Northwest China (n=4573)	Northeast China (n=4517)	Others (n=2862)
Hypertension, n (%)	3166 (15.76%)	1829(15.80%)	1490(16.15%)	1245(16.27%)	956(15.73%)	691(15.11%)	753(16.67%)	475(16.60%)
Diabetes, n (%)	723(3.60%)	424(3.66%)	330(3.58%)	267(3.49%)	222(3.65%)	155(3.39%)	162(3.59%)	110(3.84%)
COPD/Night snoring, n (%)	6701(33.35%)	3833(33.12%)	3069(33.27%)	2561(33.47%)	2071(34.08%)	1569(34.31%)	1578(34.93%)	891(31.13%)
HF, n (%)	273(1.36%)	168(1.45%)	138(1.50%)	106(1.39%)	91(1.50%)	61(1.33%)	85(1.88%)	37(1.29%)
Hyperthyroidism, n (%)	262(1.30%)	156(1.35%)	138(1.50%)	101(1.32%)	73(1.20%)	71(1.55%)	86(1.90%)	37(1.29%)
CAD, n (%)	569(2.83%)	364(3.14%)	266(2.88%)	228(2.98%)	183(3.01%)	124(2.71%)	137(3.03%)	84(2.94%)

* C2HEST score: C2: CAD/COPD (1 point each); H: hypertension (1 point); E: elderly (age ≥ 75 years, 2 points); S: systolic HF (2 points); and T: thyroid disease (hyperthyroidism, 1 point). The C2HEST score was developed to assess the individual risk of developing AF in the Asian population. (Li YG, et al. Chest. 2019). COPD: chronic obstructive pulmonary disease. HF: heart failure. CAD: coronary artery disease.

Online Figure 1: Flow chart of AF screening and the mAFA II project




MAFA: mobile Atrial Fibrillation Application. PPG: Photoplethysmography (Guo Y, et al. Int J Clin Pract. 2019 Apr 19:e13352.)


Online Figure 2: The confirmation and follow-up of individuals with “suspected” AF


* Once the notification of “suspected” AF was delivered, the participants could choose the MAFA hospitals nearby, book the doctors, then go to hospitals, receive clinical evaluation. The clinical evaluation included that the evaluation of cardiovascular risk factors, medical history, physical examination, ECG or 24-hour Holter.


Online Figure 3: Enrolment across China (n=187912)



Data visualization analysis was utilized for the enrolment across China with ECharts.
Enrolment: October 26, 2018 to May 20, 2019.

Online Figure 4: Cardiac rhythm of those with “suspected” AF

Online Figure 5: Monitoring method for first “suspected” AF

Online Figure 6: The prevalence of detected AF across China

Online Figure 7: The informed consent of AF screening and MAFA II study

The figure displays three sequential screenshots of the HUAWEI HEART STUDY(PRE-MAFA) app interface, illustrating the informed consent process for AF screening and the MAFA II study.

Screen 1: Notification

HUAWEI HEART STUDY (PRE-MAFA)
My personal heart health expert

Notification

Thank you for joining our HUAWEI HEART STUDY(PRE-MAFA)! For the sake of personal rights' insurance and personal information's security, please carefully read the following agreements with a thorough comprehension. To confirm your understanding and acceptance of the agreements, click "Agree."

[Notice] Be aware that a click on "Agree" means a fully understanding and acceptance of <HUAWEI HEART STUDY(PRE-MAFA) App Terms of Use> <HUAWEI HEART STUDY(PRE-MAFA) App Privacy Policy>. If you disagree with any content of following terms and conditions, please click "Disagree" to suspend the services.

[<HUAWEI HEART STUDY\(PRE-MAFA\) App Terms of Use>](#)
[<HUAWEI HEART STUDY\(PRE-MAFA\) App Privacy Policy>](#)

Disagree Agree

Screen 2: App Terms of Use

HUAWEI HEART STUDY(PRE-MAFA) App Terms of Use

Atrial fibrillation (AF) screening and integrated care study is initiated by Chinese PLA General Hospital.

The Mobile health technology for improved screening, patient involvement and optimizing integrated care in Atrial Fibrillation (MAFA II) study programme is developed to verify a screening and integrated care approach to improving AF management. The 'Pre-MAFA' study was the first stage of the MAFA II programme, using HUAWEI smart technology (herein referred to as the 'Huawei heart study') to test the feasibility of continuous home-monitoring with Photoplethysmograph technology. The individuals with 'suspected AF' episodes using the PPG algorithm will be further diagnosed and treatment by the health providers of the MAFA Telecare center and network hospitals.

Please be aware of the following information before you agree to participate.

A. What is Huawei heart study(PRE-MAFA)

Arrhythmia, an abnormal heart rhythm. In an arrhythmia the heartbeats may be too slow, too rapid, too irregular, or too early. Rapid arrhythmias (greater than 100 beats per minute) are called tachycardias. Slow arrhythmias (slower than 60 beats per minute) are called bradycardias. Irregular heart rhythms are called fibrillations (as in atrial fibrillation).

Atrial fibrillation is the most common type of arrhythmia in the clinic. Not only may atrial fibrillation lead to a decline in life quality and an increase in rates of hospitalization, but also the risk of stroke and heart failure may be increased by 5 and 2 times respectively. Early screening, early diagnosis, and early treatment can effectively reduce the incidence and mortality of complications such as stroke and heart failure caused by atrial fibrillation.

Screen 3: App Privacy Policy

HUAWEI HEART STUDY(PRE-MAFA) App Privacy Policy

The HUAWEI HEART STUDY(PRE-MAFA) App is a software product (or service) provided by Chinese PLA Hospital, which serves to conduct heart arrhythmia detection and manage research results for users. We fully understand the significance of privacy and will do our best to ensure the security of your personal information. We promise, we will protect your privacy according to the industry-improved security standards, professionally and securely.

Please read and understand this HUAWEI HEART STUDY(PRE-MAFA) App Privacy Policy before using our products (or services).

Please ensure that you are a responsible adult and have the entire civil capability. Furthermore, parental instructions are highly recommended for minors' use of Internet, phone and other digital devices.

If you have any question, comment or suggestion, please contact us via the service hotline 400-606-0596 (landline) or contacting online customer service.


We also have a Personal Information Protection Specialist (or Personal Information Protection Specialist) who can be reached by email at mafaii@163.com.


In general, we will respond within one month after receiving your feedback.

If our behavior of dealing personal information damaged your legal rights, you can also resolve it by external means such as filing a lawsuit in a competent people's court, complaining to an industry self-regulatory association or a government-related regulatory agency.

1. How do we collect and use your personal information?

Personal information refers to various information

Online Figure 8: Verification report of the PPG algorithm and smart devices

Online Figure 9: The distribution of monitoring time in the whole cohort

Online Figure 10 Verification report of PPG algorithm

There were four stages to develop, verify, and validate the PPG algorithm.

The pilot work has been published as follows: *Fan YY, et al. JMIR Mhealth Uhealth. 2019 Mar 5;7(3):e11437.*

The development and testification of PPG algorithm has been presented in the 2019 Cardiac Imaging & Cardiac Intervention Summit (<http://www.cici.net.cn/2019/>), and the validation of PPG algorithm (developed by HUAWEI) with 14-day monitoring, "Photoplethysmographi-based smart device for continuous detection of atrial fibrillation in a real-world setting", presented at the 2019 European Society of Cardiology Congress in Paris, France.



郑重声明

中国人民解放军总医院
心内科主任医师。副教授、
硕士生导师
美国心脏学会常委委员、
欧洲心脏病学会常委委员、
美国心脏病学会/卒中协会
专业会员、中华老年医研
院心内科专业委员会秘书
长、香港副主任委员、中华
医学学会心血管分会预防医学
组委员、中华医师协会高血
压委员会第二届青年委员、
中国老年医学会基础与转化
医学分会委员、中国生物医
学工程学会心律分会女性心
律失常工作委员会委员。

心律失常筛查算法测试报告摘要

临床心电图是一套被医学界广泛接受和认可的心律失常筛查和诊断方法。该方法的有效性已被众多文献和临床实践证实。本院以临床心电图检测结果为对照标准，测试基于华为智能穿戴设备数据的心律失常筛查算法的有效性。

房颤是最常见的心律失常疾病。2018年6月~9月，本院招募372位受试者（234位男性，138位女性；年龄18-93岁，中位数63岁；165名房颤患者，207名窦性心律人群；共3268例样本）。测试时，受试者佩戴华为智能穿戴设备并保持安静状态，由穿戴设备采集受试者的生理信号作为实测数据，由心律失常筛查算法给出分析结果。同时记录受试者的心电图，两位医师独立判读心电图，若判读结果一致，则将该结果作为金标准，若不一致则排除。对比金标准，基于华为智能穿戴设备数据的心律失常筛查算法的测试结果如下：

灵敏度：95.6%；特异性：99.4%；综合准确率：97.8%。

结果显示，基于华为智能穿戴设备数据的心律失常筛查算法给出的测试结果与临床心电图检测结果高度一致，对心律失常筛查有效。

Arrhythmia Screening Algorithm Test Report Abstract

Clinical electrocardiogram (ECG) is widely accepted by medical field as a gold standard to screen and diagnose the arrhythmia, and has been validated by literatures and clinical practices. The test result of ECG is used by the Chinese PLA General Hospital as the standard for the verification of arrhythmia screening algorithm based on the data collected by HUAWEI smart wearable devices.

Atrial fibrillation is one of the most common arrhythmia diseases. 372 subjects (234 males, 138 females; aged from 18 to 93 with the median 63; 165 atrial fibrillation patients, 207 sinus rhythm subjects, 3268 samples in total) were recruited in the arrhythmia screening algorithm test from June to September, 2018. The subjects were asked to wear HUAWEI smart wearable devices at rest state during the test. The photoplethysmography (PPG) signals were collected by the wearable devices and analysis results were given by the arrhythmia screening algorithm. The ECG was collected and interpreted by two independent physicians at the same time. If the interpreted results are consistent, then they are used as the gold standard, otherwise the results are excluded. Compared with the gold standard, the test results of arrhythmia screening algorithm based on the data collected by HUAWEI smart wearable devices are as follows:

Sensitivity: 95.6%, specificity: 99.4%, accuracy: 97.8%.

The result shows that the screening results of arrhythmia screening algorithm based on the data collected by HUAWEI smart wearable devices are highly consistent with those ECG based interpretations and effective in arrhythmia screening.



中国人民解放军总医院
心内科主任医师
（签名）
地址：北京海淀区复兴路8号
联系方式：010-55499209

Online Figure 11 Verification report of smart devices used



郭薇涛

中国人民解放军总医院

心内科主任医师、副教授、

硕士生导师

美国心脏学会荣誉委员、

欧洲心脏病协会荣誉委员、

美国心脏病协会/卒中协会

专业会员，中华老年保健研

究会心血管专业委员会秘书

长、青委副主任委员，中华

医学会心血管分会预防医学

组委员，中华医师协会高血

压委员会第二届青年委员，

中国老年医学会基础与转化

医学分会委员，中国生物医

学工程学会心律分会女性心

律失常工作委员会委员。

荣耀手环4心律失常筛查测试报告摘要

临床心电图是一套被医学界广泛接受和认可的心律失常筛查和诊断方法，该方法的有效性已被众多文献和临床实践证实。本院以临床心电图检测结果为对照标准，测试了基于荣耀手环4数据的心律失常筛查算法的有效性。

房颤是最常见的心律失常疾病。2018年9月18日~9月25日，本院招募264位受试者（129位男性，135位女性；年龄16-89岁，中位数51岁；27名房颤患者，237名正常人群，共264例样本）。测试时，受试者佩戴荣耀手环4并保持安静状态，由智能手表采集受试者的生理信号作为实测数据，由心律失常筛查算法给出分析结果。同时记录受试者的心电图，两位医师独立判读心电图，若判读结果一致，则将该结果作为金标准，若不一致则排除。对比金标准，基于荣耀手环4数据的心律失常筛查算法的测试结果如下：

灵敏度：100%；特异性：99.16%；综合准确率：99.24%。

结果显示，基于荣耀手环4数据的心律失常筛查算法给出的测试结果与临床心电图检测结果高度一致，对心律失常筛查有效。

Honor Band 4 Arrhythmia Screening Module Test Report Abstract

Clinical electrocardiogram (ECG) is widely accepted by medical field as a gold standard to screen and diagnose the arrhythmia, and has been validated by literatures and clinical practices. The test result of ECG is used by the Chinese PLA General Hospital as the standard for the verification of arrhythmia screening module based on the data collected by Honor Band 4.

Atrial fibrillation is one of the most common arrhythmia diseases. 264 subjects (129 males, 135 females; aged from 16 to 89 with the median 51; 27 atrial fibrillation patients, 237 sinus rhythm subjects, 264 samples in total) were recruited in the arrhythmia screening module test from Sept. 18, 2018 to Sept. 25, 2018. The subjects were asked to wear Honor Band 4 at rest state during the test. The photoplethysmography (PPG) signals were collected by the smart watch and analysis results were given by the arrhythmia screening module. The ECG was collected and interpreted by two independent physicians at the same time. If the interpreted results are consistent, then they are used as the gold standard, otherwise the results are excluded. Compared with the gold standard, the test results of arrhythmia screening module based on the data collected by Honor Band 4 are as follows:

Sensitivity: 100%, specificity: 99.16%, accuracy: 99.24%.

The result shows that the screening results of arrhythmia screening module based on the data collected by Honor Band 4 are highly consistent with those ECG based interpretations and effective in arrhythmia screening.

中国人民解放军总医院 心内科主任医师

(签名)

地址

联系方式

北京市西城区黄城根街28号

010-55499209



郭豫涛

中国人民解放军总医院

心内科主任医师、副教授、

硕士生导师

美国心脏学会荣誉委员、

欧洲心脏病协会荣誉委员、

美国心脏病协会/卒中协会

专业会员，中华老年保健研

究会心血管专业委员会秘书

长、青委副主任委员，中华

医学会心血管分会预防医学

组委员，中华医师协会高血

压委员会第二届青年委员、

中国老年医学会基础与转化

医学分会委员，中国生物医

学工程学会心律分会女性心

律失常工作委员会委员。

HUAWEI WATCH GT智能手表心律失常筛查测试报告摘要

临床心电图是一套被医学界广泛接受和认可的心律失常筛查和诊断方法，该方法的有效性已被众多文献和临床实践证实。本院以临床心电图检测结果为对照标准，测试了基于HUAWEI WATCH GT智能手表数据的心律失常筛查算法的有效性。

房颤是最常见的心律失常疾病。2018年9月18日~9月25日，本院招募212位受试者（123位男性，89位女性；年龄16-89岁，中位数45岁；22名房颤患者，190名正常人群，共212例样本）。测试时，受试者佩戴HUAWEI WATCH GT智能手表并保持安静状态，由智能手表采集受试者的生理信号作为实测数据，由心律失常筛查算法给出分析结果。同时记录受试者的心电图，两位医师独立判读心电图，若判读结果一致，则将该结果作为金标准，若不一致则排除。对比金标准，基于HUAWEI WATCH GT智能手表数据的心律失常筛查算法的测试结果如下：

灵敏度：100%；特异性：98.95%；综合准确率：99.06%。

结果显示，基于HUAWEI WATCH GT智能手表数据的心律失常筛查算法的测试结果与临床心电图检测结果高度一致，对心律失常筛查有效。

HUAWEI WATCH GT Arrhythmia Screening Test Report Abstract

Clinical electrocardiogram (ECG) is widely accepted by medical field as a gold standard to screen and diagnose the arrhythmia, and has been validated by literatures and clinical practices. The test result of ECG is used by the Chinese PLA General Hospital as the standard for the verification of arrhythmia screening module based on the data collected by HUAWEI WATCH GT.

Atrial fibrillation is one of the most common arrhythmia diseases. 212 subjects (123 males, 89 females; aged from 16 to 89 with the median 45; 22 atrial fibrillation patients, 190 sinus rhythm subjects, 212 samples in total) were recruited in the arrhythmia screening module test from Sept. 18, 2018 to Sept. 25, 2018. The subjects were asked to wear HUAWEI WATCH GT at rest state during the test. The photoplethysmography (PPG) signals were collected by the smart watch and analysis results were given by the arrhythmia screening module. The ECG was collected and interpreted by two independent physicians at the same time. If the interpreted results are consistent, then they are used as the gold standard. Or the results are excluded. Compared with the gold standard, the test results of arrhythmia screening module based on the data collected by HUAWEI WATCH GT are as follows:

Sensitivity: 100%, specificity: 98.95%, accuracy: 99.06%.

The result shows that the screening results of arrhythmia screening module based on the data collected by HUAWEI WATCH GT are highly consistent with those ECG based interpretations and effective in arrhythmia screening.

中国人民解放军总医院，心内科主任医师

(签名)

地址

郭豫涛

北京市西城区德胜门内大街28号

联系方式

010-55489209